PT1223966E - Utilizacao do gdnf para tratamento de defeitos na cornea - Google Patents

Utilizacao do gdnf para tratamento de defeitos na cornea

Info

Publication number
PT1223966E
PT1223966E PT00983097T PT00983097T PT1223966E PT 1223966 E PT1223966 E PT 1223966E PT 00983097 T PT00983097 T PT 00983097T PT 00983097 T PT00983097 T PT 00983097T PT 1223966 E PT1223966 E PT 1223966E
Authority
PT
Portugal
Prior art keywords
gdnf
cornea
defects
take
agonist
Prior art date
Application number
PT00983097T
Other languages
English (en)
Inventor
Michael Paulista
Michael Hanke
Friedrich Kruse
Jens Pohl
Original Assignee
Biopharm Ges Biotechn Entwickl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Ges Biotechn Entwickl filed Critical Biopharm Ges Biotechn Entwickl
Publication of PT1223966E publication Critical patent/PT1223966E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00983097T 1999-10-29 2000-10-30 Utilizacao do gdnf para tratamento de defeitos na cornea PT1223966E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99121597 1999-10-29

Publications (1)

Publication Number Publication Date
PT1223966E true PT1223966E (pt) 2003-09-30

Family

ID=8239299

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00983097T PT1223966E (pt) 1999-10-29 2000-10-30 Utilizacao do gdnf para tratamento de defeitos na cornea

Country Status (11)

Country Link
US (1) US20030166537A1 (pt)
EP (1) EP1223966B1 (pt)
JP (1) JP2003512433A (pt)
AT (1) ATE238806T1 (pt)
AU (1) AU1997501A (pt)
CA (1) CA2385929A1 (pt)
DE (1) DE60002496T2 (pt)
DK (1) DK1223966T3 (pt)
ES (1) ES2198367T3 (pt)
PT (1) PT1223966E (pt)
WO (1) WO2001030375A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
EP2058329B1 (en) 2003-06-10 2010-08-18 NsGene A/S Improved secretion of neublastin
WO2005051415A1 (en) 2003-11-27 2005-06-09 Develogen Aktiengesellschaft Method for preventing and treating diabetes using neurturin
US20050209148A1 (en) * 2004-02-20 2005-09-22 Arnon Rosenthal Methods of treating obesity or diabetes using NT-4/5
CA2561577A1 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
WO2006023782A2 (en) 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Refolding transforming growth factor beta family proteins
CN102924585A (zh) * 2004-08-19 2013-02-13 比奥根艾迪克Ma公司 神经胚素变体
NL2000464C2 (nl) * 2006-02-02 2007-09-11 Rinat Neuroscience Corp Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist.
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション trkBアンタゴニストを投与することにより肥満を治療する方法
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
WO2008070513A1 (en) * 2006-12-01 2008-06-12 Alcon Research, Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
BRPI0720473A2 (pt) * 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2009011892A2 (en) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP5429865B2 (ja) * 2009-09-15 2014-02-26 学校法人日本大学 生体外創傷治癒試験用用具または創傷作製方法
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
JP6403217B2 (ja) 2013-07-30 2018-10-10 京都府公立大学法人 角膜内皮ecm治療薬
CN107137698A (zh) * 2017-03-03 2017-09-08 北京大学第三医院 一种包含gdnf的用于治疗角膜上皮损伤的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
WO1997049798A1 (en) * 1996-06-27 1997-12-31 University Of Helsinki Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth, and of enteric innervation
KR20000070357A (ko) * 1997-01-23 2000-11-25 다께우찌 마사야쓰 당뇨병 치료제

Also Published As

Publication number Publication date
DE60002496T2 (de) 2004-03-25
ES2198367T3 (es) 2004-02-01
WO2001030375A3 (en) 2002-03-21
AU1997501A (en) 2001-05-08
EP1223966A2 (en) 2002-07-24
US20030166537A1 (en) 2003-09-04
EP1223966B1 (en) 2003-05-02
DE60002496D1 (de) 2003-06-05
ATE238806T1 (de) 2003-05-15
JP2003512433A (ja) 2003-04-02
WO2001030375A2 (en) 2001-05-03
CA2385929A1 (en) 2001-05-03
DK1223966T3 (da) 2003-08-18

Similar Documents

Publication Publication Date Title
PT1223966E (pt) Utilizacao do gdnf para tratamento de defeitos na cornea
DE69739169D1 (de) Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen
BR0312563A (pt) Comprimido de lasofoxifeno e seu revestimento
ES2702602T3 (es) Fabricación de construcciones tridimensionales elásticas escalables
AR020055A1 (es) Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
PT1061940E (pt) Utilizacao de foliestatina para a producao de um medicamento para o tratamento de disturbios relacionados com os musculos
NO20010531L (no) Medisinske aerosolformuleringer
ATE251448T1 (de) Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
US20190322702A1 (en) Tricalcium Phosphate Binding Peptides And Uses Thereof
DE60023600D1 (de) Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
ES2183510T3 (es) Composiciones de proteinas de matriz para la cicatrizacion de heridas.
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE60137978D1 (de) Zusammensetzung zur förderung des haarwachstums
PT775159E (pt) Novo processo de producao de proteina dimerica biologicamente activa
WO2003033808A3 (en) Composition and method for treating diabetes
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
DK0935652T3 (da) Keratinocyt vækstfaktor-2 produkter
MX9301535A (es) Material proteinaceo biologicamente activo aislado y purificado.
EP1801232A4 (en) METHOD FOR SORTING TRANSMEMBRANE ENZYME INHIBITOR SUBSTANCE
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
WO2001068643A3 (fr) Nouveaux derives heterocycliques ou benzeniques de l'acide lipoique, leur preparation et leur application a titre de medicaments
DE69939586D1 (de) Inhibitoren für die gefässneubildung
NO20014891D0 (no) Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser